bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
Since 2017, the FDA has quickly adjusted processes, expanded capabilities, and created new guidelines specifically for ATMPs to keep up with the pace of the industry and discover and penalize developers who do not abide by regulations.
Infectious diseases are responsible for millions of deaths worldwide. When COVID-19 containment measures were established, the transmission of these deadly pathogens was reduced, leading to a significant reduction in life-threatening invasive diseases in many countries worldwide.
Three ATMP experts recently discussed how the COVID-19 pandemic has impacted pharmaceutical quality control processes and the main takeaways for new ATMP developers.
See how the PASTEUR Act, a bipartisan House and Senate bill introduced in September 2020, aims to support the development of new antibiotics alongside antimicrobial stewardship.
At this year’s World Anti-Microbial Resistance Congress, Dr. Tristan Timbrook delivered a...
WASH, which stands for water, sanitation, and hygiene, are basic...